IISc Engineers Target Sub-$2,500 “Artificial Pancreas” to Revolutionize India’s Type 1 Diabetes Care

BENGALURU, INDIA — In a major step toward making advanced medical technology accessible to millions, researchers at the Indian Institute of Science (IISc) are developing an artificial intelligence-driven diabetes ecosystem designed to lower the cost of automated insulin delivery by more than 60 percent.

The project, spearheaded by Prof. Radhakant Padhi of IISc’s Department of Aerospace Engineering, combines a new predictive mobile application called SugarSight with an indigenous “closed-loop” artificial pancreas. By adapting control algorithms originally engineered for aerospace autopilot guidance systems, the researchers aim to deliver automated, real-time blood glucose management tailored specifically to the physiological parameters of Indian patients.

If successfully validated and certified, the system could drop the price barrier for closed-loop diabetes systems in India from commercial rates of roughly ₹6 lakh ($7,200 USD) to approximately ₹2 lakh ($2,400 USD).

How the SugarSight Artificial Pancreas Operates

For people living with Type 1 diabetes, everyday life involves a relentless balancing act. Because the pancreas stops producing insulin—a hormone crucial for moving glucose from food into cells for energy—patients must manually measure blood sugar and calculate insulin doses multiple times a day.

The IISc technology works like a biological cruise control, mimicking the self-regulating feedback system of a healthy human pancreas.

               ┌──────────────────────────────┐
               │  Continuous Glucose Monitor  │
               │   (Reads Interstitial Fluid) │
               └──────────────┬───────────────┘
                              │ Real-Time Glucose Data
                              ▼
┌───────────────────────────────────────────────────────────┐
│               Smartphone App (SugarSight)                 │
│  - Model Predictive Control Algorithm                     │
│  - Analyzes Glucose Trends, Diet, Exercise & Sensitivity  │
│  - Calculates Optimal Dose Every Few Minutes              │
└──────────────┬────────────────────────────────────────────┘
               │ Wireless Delivery Command
               ▼
               ┌──────────────────────────────┐
               │    Subcutaneous Micro-Pump    │
               │  (Delivers Precise Insulin)  │
               └──────────────────────────────┘

The system integrates three core components into a synchronized loop:

1. Continuous Glucose Monitor (CGM): A tiny sensor applied to the skin that continually measures glucose levels in interstitial fluid (the fluid between cells).

2. Control Algorithm (SugarSight): Housed inside a smartphone app, this “electronic brain” uses Model Predictive Control (MPC) to evaluate real-time sugar trends, physical activity, food intake, and personal insulin sensitivity.

3. Insulin Pump: A compact, wearable micro-device that receives wireless commands from the app to infuse precise, micro-doses of rapid-acting insulin beneath the skin.

“A person typically requires only about half a millilitre of insulin over a 24-hour period,” explained Prof. Padhi during a public presentation of the system. “Such tiny quantities cannot be administered manually and require a pump capable of delivering highly accurate doses. Even a slight overdose can result in hypoglycemia, while an underdose can leave blood sugar levels dangerously high.”

From Flight Guidance to Human Physiology

The interdisciplinary leap from rocket guidance to endocrinology is not as far-fetched as it sounds. In aerospace engineering, high-performance autopilots must dynamically recalculate trajectory to compensate for atmospheric turbulence. Similarly, the human body experiences constant “biological turbulence”—from exercise and stress to fluctuating digestion rates.

By applying algorithms tested on UVA-Padova flight simulation software and localized trial data, SugarSight continuously forecasts whether a patient’s blood glucose will spike or crash over the next several hours. The platform also features automated noise-correction routines to resolve sensor errors that frequently trip up standard monitors.

Clinical Progress and Early Benchmarks

The IISc platform has been in development for nearly a decade, supported by IISc’s Foundation for Science Innovation and Development (FSID) and the Robert Bosch Centre for Cyber-Physical Systems.

An early pilot trial conducted in collaboration with endocrinologists at MS Ramaiah Medical College evaluated a precursor system across 10 adults with Type 1 diabetes.

Following those initial field tests, the IISc team redesigned their hardware into the improved Mark-2 prototype. The updated prototype has completed initial laboratory demonstrations and is undergoing redevelopment to meet strict central medical device safety certifications.

What Medical Experts Say

Global health authorities recognize automated insulin delivery as a transformative milestone in chronic disease management. According to guidelines from the U.S. Food and Drug Administration (FDA), artificial pancreas systems significantly reduce the daily cognitive load on patients while preventing severe glycemic excursions.

However, diabetes specialists caution that current technologies—including the IISc platform—remain hybrid closed-loop systems rather than fully autonomous “set-and-forget” units.

“Continuous glucose monitoring and insulin pump technologies have significantly reduced the burden of diabetes management by minimizing painful finger-prick tests,” notes Dr. Mala Dharmalingam, a senior endocrinologist familiar with diabetes technology developments. “However, patients must still enter meal announcements and maintain vigilance. Technology supports clinical judgment; it does not replace patient education.”

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) similarly highlights that while automated pumps effectively prevent nocturnal hypoglycemia (overnight blood sugar crashes), user intervention remains critical during high-carbohydrate meals or intense physical exercise.

Public Health Impact: Addressing India’s Diabetes Crisis

According to International Diabetes Federation estimates, India is home to over 74 million adults living with diabetes, a figure projected to cross 125 million by 2045. While Type 2 accounts for the vast majority of cases, hundreds of thousands of Indian children and young adults live with Type 1 diabetes, requiring life-long insulin therapy.

In low- and middle-income regions, imported continuous glucose monitors and commercial smart pumps remain financially out of reach for over 90 percent of affected families. Chronic high blood sugar (hyperglycemia) drastically increases the long-term risk of kidney failure (nephropathy), blindness (retinopathy), and nerve damage (neuropathy). Conversely, acute low blood sugar (hypoglycemia) can trigger seizures or loss of consciousness.

By cutting hardware and software costs down to approximately ₹2 lakh, the IISc initiative could make closed-loop therapy viable for public hospital networks and mid-tier healthcare centers across South Asia.

Limitations and Road Ahead

While the SugarSight and artificial pancreas developments are encouraging, several hurdles remain before the platform reaches pharmacy shelves:

1. Regulatory Hurdles: Medical devices delivering life-sustaining drugs face stringent regulatory approval pathways. The Mark-2 prototype must undergo rigorous multi-center clinical trials to prove efficacy and fail-safe safety.

2. Hardware Reliability: Sensor calibration drift and pump occlusion (tubing blockages) remain universal challenges in diabetes engineering.

3. User Compliance: AI algorithms rely on accurate real-time data input from users regarding meal carbohydrate counts.

For patients and families navigating Type 1 diabetes today, experts recommend continuing established regimens under physician guidance rather than delaying treatment decisions in anticipation of experimental devices. Nevertheless, IISc’s aerospace-inspired innovation signals a bright future where high-tech diabetes care becomes an affordable reality for all.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

https://health.economictimes.indiatimes.com/news/industry/iisc-develops-ai-platform-eyes-affordable-artificial-pancreas-for-diabetes-care/132507447?utm_source=latest_news&utm_medium=homepage